Money is moving into energy, materials, ‌staples, and industrials, Citigroup notes

Reuters: Cheaper, smaller stocks benefitting from risk aversion in tech sector

Bank of America Corporation

The Magnificent Seven's market leadership faces a "major threat"

BofA calls smid-cap stocks 'best play' ahead of U.S. midterms

Pandora A/S

Shares of Danish jewellery giant Pandora rose 5.6% in trading in Copenhagen on Thursday and continued higher after early trading on Friday. Despite weak guidance for 2026 and the suspension of share buybacks, the stock was supported by falling silver prices, Bloomberg <a href="https://www.bloomberg.com/news/articles/2026-02-05/pandora-sees-sales-slowing-pauses-buyback-as-silver-prices-bite?embedded-checkout=true#:~:text=Shares%20rose%20as%20much%20as%207.5%25%20in%20Copenhagen%20as%20silver%20prices%20tumbling%20outweighed%20concerns%20around%20guidance.">reported</a>. A day earlier, Pandora announced plans to partially shift away from the precious metal in favor of platinum-plated jewelry. On Friday, several analysts revised their target price on the company’s shares.

Pandora cuts sales guidance and pauses buybacks, but the stock is still rising

Janux Therapeutics, Inc.

Legend Biotech Corporation

4D Molecular Therapeutics, Inc.

Arcturus Therapeutics Holdings Inc.

Altimmune, Inc.

Black Diamond Therapeutics, Inc.

The global biotechnology market was valued at about $1.65 trillion in 2025 and is projected to grow to $5.22 trillion by 2034 at a compound annual growth rate of 13.67%, according to <a href="https://straitsresearch.com/report/biotechnology-market">Straits Research</a>. The U.S. market remains the largest globally: it was worth $552.39 billion in 2023 and is expected to reach $1.24 trillion by 2030. Insider Monkey has <a href="https://www.insidermonkey.com/blog/20-best-biotech-stocks-under-20-to-buy-now-1685703/">selected</a>&nbsp;20 biotech companies trading below $20 per share that are widely held by hedge funds.

Insider Monkey names 20 under-$20 biotech stocks popular with hedge funds

Janux Therapeutics – a small-cap developer of prostate cancer therapies – has lost more than 65% of its market value over the past year. The steepest decline followed the release of data on one of the key candidates in the company’s pipeline. Despite this, Janux shares remain in the portfolios of BlackRock and investor Steve Cohen, according to its <a href="https://www.gurufocus.com/stock/JANX/ownership">Form 13F filing</a> as of the end of September. Wall Street analysts, for their part, continue to recommend buying the stock, expecting it could rise more than 300%.

Why biotech Janux, held by Blackrock and Steve Cohen, has consensus upside of 300%

M-tron Industries, Inc.

Espey Mfg. & Electronics Corp.

NioCorp Developments Ltd.

Western Copper and Gold Corporation

In the autumn, Freedom Broker analysts <a href="https://en.oninvest.com/article/freedom-picks-five-small-caps-two-strategies-as-market-enters-goldilocks-mode">noted</a>&nbsp;that a Goldilocks mode had begun to take effect in the U.S. economy – a combination of steady growth, normalized inflation, and a labor market supported by a neutral-to-soft policy by the Fed. Under such conditions, two strategies remain the most logical and advisable: investing in dividend stocks amid falling rates or in growth stocks while business activity remains robust, according to Vadim Merkulov, director of research at Freedom Finance Global.

Two strategies, four small caps from Freedom for February and beyond

Liberty Latin America Ltd.

Atlanta Braves Holdings, Inc.

Schrodinger, Inc.

Ramaco Resources, Inc.

Via Transportation

Alongside well known public companies, large investors also hold small positions in businesses with market capitalization of up to $2 billion. As a rule, these are targeted investments in infrastructure, real assets, or undervalued companies that have yet to attract broad market attention. Analyst Aldiyar Anuarbekov reviewed, for <i>Oninvest,&nbsp;</i>which small caps leading investment figures are backing.

Which small caps Buffett, Gates, and Ackman are betting on

Inuvo, Inc.

Shares of Inuvo, a small-cap provider of AI-based marketing technology, <a href="https://finance.yahoo.com/quote/INUV/">sank</a>&nbsp;more than 26% in early trading on Thursday, January 29, after the company released two pieces of news: a sharp year-over-year&nbsp;<a href="https://inuvo.com/inuvo-reports-unaudited-preliminary-fourth-quarter-2025-revenue-results/">decline</a>&nbsp;of 47%&nbsp;in fourth-quarter revenue, on preliminary numbers, and a <a href="https://inuvo.com/inuvo-appoints-rob-buchner-as-chairman-and-chief-executive-officer/">change at CEO</a>.

Shares of AI ad company Inuvo sink 26% on preliminary 4Q plunge in revenue

Getty Realty Corp.

DiamondRock Hospitality Company

Addus HomeCare Corporation

Envista Holdings Corporation

Waystar Holding Corp.

Doximity, Inc.

Boot Barn Holdings, Inc.

Boyd Gaming Corporation

BILL Holdings, Inc.

ESAB Corporation

BofA Securities has <a href="https://www.barrons.com/articles/10-small-cap-stocks-poised-to-break-out-11afcafe?mod=RTA">identified</a>&nbsp;10 small- and mid-cap companies that investors should pay attention to as the segment tries to extend its recent rally. BofA screened for stocks that delivered better-than-expected earnings and sales in the third quarter, and for which its analysts’ fourth-quarter estimates exceed Wall Street consensus forecasts, <i>Barron's </i>reports.

BofA picks 10 smid-cap stocks that may beat Wall Street's 4Q expectations

Compass, Inc.

Anywhere Real Estate Inc.

Real estate broker Compass has evolved from a local startup into a company with a market capitalization of nearly $10 billion, offering a new approach to home sales based on the gradual release of listings from exclusive access into the open market. In January, Compass closed a merger with peer Anywhere Real Estate. The combined brokerage will control nearly 20% of U.S. home sales. Analysts believe the transaction could support Compass’ market position and share price, despite antitrust risks and persisting uncertainty around the housing market.

Real estate broker Compass closes Anywhere merger. What does this mean for the stock?

Cardiff Oncology, Inc.

Shares of Cardiff Oncology, a micro-cap developer of a drug targeting a specific form of colorectal cancer, <a href="https://finance.yahoo.com/quote/CRDF/">plunged</a>&nbsp;32% on Tuesday, January 27. Investors reacted to the company’s <a href="https://investors.cardiffoncology.com/news-releases/news-release-details/cardiff-oncology-announces-executive-leadership-changes-it">announcement</a>&nbsp;of an immediate management reshuffle. The selloff came despite the <a href="https://investors.cardiffoncology.com/news-releases/news-release-details/cardiff-oncology-announces-positive-update-its-randomized-phase">release of positive clinical data</a> for its lead drug later the same day, as well as the company’s explanation that the executive changes reflected a transition to a new stage of development.

Cardiff Oncology plunges 32% amid management reshuffle, despite upbeat trial data

Redwire Corporation

Shares of Redwire, a mid-cap maker of spacecraft and technologies for building infrastructure on Mars, <a href="https://finance.yahoo.com/quote/RDW/">surged</a>&nbsp;nearly 30% on Tuesday, January 27, to their highest levels since mid-2025. Investors were reacting to the <a href="https://ir.redwirespace.com/news-events/press-releases/detail/215/redwire-selected-for-missile-defense-agencys-151">announcement</a>&nbsp;that the company had been selected as one of the vendors under a $151 billion U.S. Missile Defense Agency program.

Small caps